オプションチェーンは、BioHarvest Sciencesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、BioHarvest Sciencesの市場センチメントを評価します。.

BioHarvest Sciences (NASDAQ:BHST) 株価情報, オプションチェーン

BioHarvest Sciences

BioHarvest Sciences Inc. - Common Stock

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

BioHarvest Sciences Inc

Citigroup analyst Ariel Rosa maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Neutral and lowers the price target from $205 to $186.

News

Price Target

Analyst Ratings

ODFL

Citigroup Maintains Neutral on Old Dominion Freight Line, Lowers Price Target to $186

Citigroup analyst Ariel Rosa maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $544 to $498.

SAIA

Citigroup Maintains Buy on Saia, Lowers Price Target to $498

Maxim Group analyst Allen Klee maintains Cryo-Cell International (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CCEL#AMEX">CCEL</a>) with a Buy and lowers the price target from $9 to $8.5.

CCEL

Maxim Group Maintains Buy on Cryo-Cell International, Lowers Price Target to $8.5

Lake Street analyst Ben Haynor maintains Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) with a Buy and lowers the price target from $2 to $1.

EKSO

Lake Street Maintains Buy on Ekso Bionics Holdings, Lowers Price Target to $1

Lake Street analyst Ryan Meyers maintains GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) with a Buy and lowers the price target from $50 to $26.

Lake Street Maintains Buy on GigaCloud Tech, Lowers Price Target to $26

Loop Capital analyst Ananda Baruah maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Buy and lowers the price target from $150 to $130.

NTAP

Loop Capital Maintains Buy on NetApp, Lowers Price Target to $130

Loop Capital analyst Ananda Baruah maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Buy and lowers the price target from $185 to $130.

DELL

Loop Capital Maintains Buy on Dell Technologies, Lowers Price Target to $130

Loop Capital analyst Ananda Baruah maintains HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) with a Hold and lowers the price target from $35 to $30.

Loop Capital Maintains Hold on HP, Lowers Price Target to $30

Zomedica Reports Transition To OTCQB Venture Market, Common Shares To Be Delisted From NYSE American Exchange

Carlisle Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) has outperformed the market over the past 5 years by 2.48% on an annualized basis producing an average annual return of 18.51%. Currently, Carlisle Companies has a market capitalization of $14.56 billion. 
Buying $1000 In CSL: If an investor had bought $1000 of CSL stock 5 years ago, it would be worth $2,266.80 today based on a price of $326.85 for CSL at the time of writing.
<h3>Carlisle Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741129214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Carlisle Companies 5 Years Ago Would Be Worth This Much Today

Loop Capital analyst Alton Stump maintains FAT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAT#NASDAQ">FAT</a>) with a Buy and lowers the price target from $15 to $12.

Loop Capital Maintains Buy on FAT Brands, Lowers Price Target to $12

Loop Capital analyst Jeffrey Stevenson maintains Installed Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>) with a Buy and lowers the price target from $230 to $215.

Loop Capital Maintains Buy on Installed Building Prods, Lowers Price Target to $215

Jefferies analyst Jonathan Matuszewski maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Buy and lowers the price target from $106 to $92.

Jefferies Maintains Buy on Best Buy Co, Lowers Price Target to $92

Jefferies analyst Thomas Chong maintains Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) with a Buy and raises the price target from $131 to $157.

Jefferies Maintains Buy on Sea, Raises Price Target to $157

Jefferies analyst Corey Tarlowe maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Buy and lowers the price target from $165 to $150.

Jefferies Maintains Buy on Target, Lowers Price Target to $150

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) has outperformed the market over the past 20 years by 2.01% on an annualized basis producing an average annual return of 10.16%. Currently, JPMorgan Chase has a market capitalization of $704.73 billion. 
Buying $100 In JPM: If an investor had bought $100 of JPM stock 20 years ago, it would be worth $688.26 today based on a price of $252.04 for JPM at the time of writing.
<h3>JPMorgan Chase's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741128309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In JPMorgan Chase 20 Years Ago Would Be Worth Today

Janney Montgomery Scott analyst Thomas Meric downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Buy to Neutral and announces $1 price target.

Downgrades

NOVA

Janney Montgomery Scott Downgrades Sunnova Energy Intl to Neutral, Announces $1 Price Target

The transaction is subject to regulatory approval and is expected to close during the second quarter of 2025.
Woodruff Sawyer&nbsp;pro forma revenues and EBITDAC (including expected synergies) for the trailing 12 months ended December 31, 2024 were approximately $268 million and $88 million, respectively.
Integration costs and expected non-cash management retention costs are expected to total $150 million over the next 3 years.
&nbsp;

Arthur J. Gallagher Agrees To Acquire San Francisco, California-based Woodruff Sawyer For Consideration Of $1.2B

DA Davidson analyst Manuel Navas initiates coverage on Eagle Financial Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSI#NASDAQ">EFSI</a>) with a Buy rating and announces Price Target of $40.

Comments

BioHarvest Sciences

BioHarvest Sciences (BHST) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル